Medpace (NASDAQ:MEDP) CEO August Troendle Sells 17,610 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 17,610 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $605.11, for a total value of $10,655,987.10. Following the completion of the transaction, the chief executive officer directly owned 615,802 shares in the company, valued at approximately $372,627,948.22. This represents a 2.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Medpace Stock Down 1.4%

Shares of MEDP stock opened at $596.98 on Thursday. The business has a 50-day moving average price of $531.28 and a two-hundred day moving average price of $491.78. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90. The firm has a market cap of $16.66 billion, a P/E ratio of 34.99, a price-to-earnings-growth ratio of 2.70 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the company earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on MEDP. Truist Financial lifted their target price on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. TD Cowen upped their price target on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and raised their price objective for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Leerink Partners set a $620.00 price objective on Medpace in a report on Thursday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Two equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. According to data from MarketBeat, Medpace presently has an average rating of “Hold” and an average target price of $584.18.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. NewEdge Advisors LLC grew its holdings in Medpace by 22.1% in the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after acquiring an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Medpace by 3.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after acquiring an additional 3,010 shares during the period. Geneos Wealth Management Inc. raised its stake in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Sivia Capital Partners LLC bought a new position in shares of Medpace during the second quarter valued at about $296,000. Finally, M&T Bank Corp boosted its holdings in shares of Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after purchasing an additional 31 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.